{"id":"W4285389858","doi":"10.1080/10428194.2022.2092853","title":"Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia","year":2022,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Myeloid leukemia; Refractory (planetary science); Pharmacokinetics; Antibody; Oncology; Pharmacology; Internal medicine; Immunology; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009668483,0.0008059519,0.001824165,0.000176864,0.0004235735,0.0009497554,0.0006809014,0.002496543,0.002908799],"category_scores_gemma":[0.001145022,0.0003976721,0.0008400729,0.0002751933,0.0005881461,0.0007809001,0.0001733703,0.004352326,0.0009197977],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001367424,"about_ca_system_score_gemma":0.0009105891,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007541444,"about_ca_topic_score_gemma":0.002205594,"domain_scores_codex":[0.9996712,0.0001606294,0.00001657778,0.00006333592,0.00003379624,0.00005447228],"domain_scores_gemma":[0.9993445,0.0002202559,0.00009169677,0.00004358295,0.00004105226,0.0002587558],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6620615,0.04420434,0.01206845,0.0008306926,0.001636516,0.003830081,0.0004514279,0.003686466,0.04732026,0.001284511,0.03225907,0.1903667],"study_design_scores_gemma":[0.6562608,0.2911764,0.01656947,0.00006379603,0.0005058127,0.002329121,0.0001065982,0.00480984,0.004800091,0.001051546,0.02227089,0.00005551884],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9710764,0.005140556,0.001651745,0.009909914,0.001540465,0.001782761,0.002188501,0.0001715694,0.006538033],"genre_scores_gemma":[0.9784985,0.001577684,0.001981578,0.009156489,0.000923013,0.00109988,0.001646057,0.00004309174,0.005073708],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002908799,"threshold_uncertainty_score":0.009921372,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03969756535386425,"score_gpt":0.3630186783913506,"score_spread":0.3233211130374863,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}